Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study

Table 1

Efficacy of canagliflozin add-on therapy on various metabolic parameters.

Parameters	Baseline	12 weeks		Baseline	12 weeks
Group	Teneligliptin continued group			Canagliflozin add-on group
Age (years)		—	—		—	—
Gender (M/F)	21/14	—	—	27/29	—	—
DM duration (years)		—	—		—	—
Body weight (kg)			n.s.			<0.0001
BMI (kg/m^2)			n.s.			<0.0001
Fat mass (kg)	—	—	—			<0.0001
Visceral fat area (cm^2)	—	—	—			<0.0001
Skeletal muscle mass (kg)	—	—	—			0.047
FPG (mg/dL)			n.s.			<0.0001
HbA1c (%)			n.s.			<0.0001
IRI (μIU/mL)	—	—	—			n.s.
Glucagon (pg/mL)	—	—	—			0.0010
IRI/glucagon	—	—	—			n.s.
Systolic BP (mmHg)			n.s.			0.0041
Diastolic BP (mmHg)			n.s.			0.032
AST (U/L)		2	n.s.			n.s.
ALT (U/L)			n.s.			0.031
γGTP (U/L)			n.s.			0.0005
Cre (mg/dL)			n.s.			n.s.
BUN (mg/dL)			n.s.			<0.0001
eGFR (mL/min/1.73 m^2)			n.s.			n.s.
Triglyceride (mg/dL)			n.s.			n.s.
HDL cholesterol (mg/dL)			n.s.			n.s.
LDL cholesterol (mg/dL)			n.s.			n.s.
Ketone body (μmol/L)	—	—	—			0.024
Uric acid (mg/dL)			n.s.			<0.0001
Urinary albumin excretion (mg/g. Cre)		—	—			0.020
Urinary glucose excretion (mg/g. Cre)	—	—	—			<0.0001

Teneligliptin continued group vs. canagliflozin add-on group at baseline (Wilcoxon rank sum test), .